Human NK Resistant Tumor Cell Lysis is Effected by IL-2 Activated Killer Cells

  • Elizabeth A. Grimm
  • Anthony A. Rayner
  • Debra J. Wilson
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 187)


In experimental animal systems, trarlsfer of cell populations immune to solid tumors has been successful in mediating the regression of such tumors. In human systems, much conflicting and confusing data has been reported attempting to define the analogous effector cells. Our approach to define human anti-tumor effectors cells was to avoid as many in vitro induced artifacts as possible, and to employ fresh (or cyropreserved, uncultured) surgical biopsy specimens of tumors as target cells, and to generate effectors in human serum with naturally occurring immune stimulants. We have found that normal or cancer patients1 PBL incubated for 2–3 days in preparations of IL-2, including purified recombinant IL-2 (RIL-2) acquires the unique capacity to kill human tumors in 4 hour chromium release assays (1–6). These lymphokine-activated killer cells (LAK) kill NK resistant fresh tumors with an efficiency and polyspecificity that has not been found reproducible in any other anti-tumor lytic system, and therefore provides yet another interesting and potentially biologically relevant system in which to examine the mechanism of cell mediated cytotoxicity. This report addresses some of the basic aspects of LAK killing, such as the killing efficiency of whole populations versus clones, kinetics of lysis as measured by the chromium release assay, correlation of chromium release with the expression of LAK effector cell markers, and morphology and phenotype of LAK effector cells, thereby setting the groundwork for further detailed studies of the mechanism of tumor killing by LAK.


Chromium Release Allogeneic Tumor Chromium Release Assay Surgical Biopsy Specimen Effector Target Ratio 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Grimm, E.A., Mazumder, A., Zhang, H.Z, and Rosenberg, S.A. The lymphokine activated killer cell phenomenon: Lysis of NK resistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155:1823–1841 (1982).PubMedCrossRefGoogle Scholar
  2. 2.
    Grimm, E.A., Gorelik, E., Rosenstein, M.M., and Rosenberg, S.A. The lymphokine-activated killer cell phenomenon: In vitro and in vivo studies. Interluekins, Lymphokines, and Cytokines. S. Cohen and J. Oppenheim,(eds.). Academic Press, New York, pp. 739–746 (1983).Google Scholar
  3. 3.
    Grimm, E.A., Ramsey, K., Mazumder, A., Wilson, D.J., Djeu, J., and Rosenberg, S.A. Lymphokine-activated killer cell phenomenon: II. The precursor phenotype is serologically distinct from peripheral T lymphocytes, memory CTL, and NK cells. J. Exp. Med. 157:884–897 (1983).PubMedCrossRefGoogle Scholar
  4. 4.
    Grimm, E.A., Robb, R.J., Roth, J.A., Neckers, L.M., Lachman, L., Wilson, D.J., and Rosenberg, S.A. The lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 alone is sufficient for direct activation of PBL into LAK. J. Exp. Med. 158:1356–1361 (1983).PubMedCrossRefGoogle Scholar
  5. 5.
    Rosenberg, S.A., Grimm, E.A., McGrogan, N., Doyle, M., Kawasaki, E., Koths, K., and Mark, D.F. Biologic activity of recombinant human interleukine-2 produced in E. Coli. Science. 223:1412–1415 (1984).Google Scholar
  6. 6.
    Grimm, E.A., and Rosenberg, S.A. The human lymphokine- activated killer cell phenomenon in Lymphokines. 9: Edgar Pick, (ed.) Academic Press, (in press).Google Scholar
  7. 7.
    Lotze, M.T., Grimm, E.A., Mazumder, A., Strausser, J.L., and Rosenberg, S.A. Lysis of human solid tumors by autologous cells sensitized in vitro to alloantigens. J. Immunol. 127:266–271 (1981).PubMedGoogle Scholar
  8. 8.
    Henney, C.S. Dintinction between NK cells and CTL in Advances in Exp. Med. Biol. 146:353–356 (1982).Google Scholar
  9. 9.
    Rosenstein, M., Yron, I., Kaufmann, Y., and Rosenberg S.A. Lymphokine-activated killer cells: Lysis of fresh syngeneic natural killer-resistent murine tumor cells by lymphocytes cultured in interleukin-2. Cancer Research. 44:1946 (1984).PubMedGoogle Scholar
  10. 10.
    Rayner, A.A., Grimm, E.A., Lotze, M.T., and Rosenberg, S.A. Demonstration of shared recognition and lysis of autologous and allogeneic fresh human tumors by cloned lymphokine-activated killer calls (LAK): Implications for immunotherapy. Surgical Forum (in press).Google Scholar
  11. 11.
    Rayner, A.A., Grimm, E.A., Lotze, M.T., Chu, E., and Rosenberg, S.A. Lymphokine-activated killer cells (LAK). Analysis of factors relevant to the immunotherapy of cancer. (submitted).Google Scholar
  12. 12.
    Rayner, A.A., Grimm, E.A., Wilson, D.J., and Rosenberg, S.A. Clonal and lytic analysis of IL-2 activated lymphocyte: Lymphokine-activated killer (LAK) cell clones lyse multiple fresh human targets, (submitted).Google Scholar
  13. 13.
    Grimm, E.A., and Bonavida, B. Mechanism of cell-mediated immunity at the single cell level. I. Estimation of cytotoxic T lymphocyte frequency and relative lytic efficiency in individual effector populations. J. Immunol. 123:2861–2869 (1979).PubMedGoogle Scholar
  14. 14.
    Zagury, D., Morgan, D., Lenoir, G., Fouchard, M., Feldman, M. Human normal CTL clones. Generatioin and properties. Int. J. Cancer. 31:427–432 (1983).PubMedCrossRefGoogle Scholar
  15. 15.
    Kaufmann, Y. Lyt 2 negative and T cell growth factor independent cytotoxic T lymphocyte hybridomas. Adv. in Exp. Med. Biol. W.R. Clark and P. Goldstein (eds.) 146 (1982).Google Scholar
  16. 16.
    Mazumder, A., and Rosenberg, S.A. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin-2 J. Exp Med. 159:495–507 (1984).PubMedCrossRefGoogle Scholar
  17. 17.
    Mule, J.J., Shut, S., Schwarz, S., and Rosenberg, S.A. Successful adoptive immunotherapy of established pulmonary metastases of multiple sarcomas with lymphokine-activated killer cells and recombinant IL-2. Science, (in press).Google Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • Elizabeth A. Grimm
    • 1
  • Anthony A. Rayner
    • 1
  • Debra J. Wilson
    • 1
  1. 1.Surgical Neurology Branch, Natl. Inst. of Neurological and Communicative Disorders and StrokeNational Institutes of HealthBethesdaUSA

Personalised recommendations